Sunday, 11 October 2026European Markets

Pharmaceutical Regulation

1 article

European Pharma in Flux: Orion Bets on R&D Growth as Global Restructuring Reshapes EU Drug Pipelines

Finland's Orion Corporation is forecasting increased R&D investment and revenue of up to €2.1 billion in 2026, signalling confidence in the European pharmaceutical landscape even as global giants restructure their operations. The broader sector is navigating a complex convergence of regulatory approvals, corporate realignments, and pipeline expansions that carry significant implications for EU-based research and drug development. European regulators and investors alike are watching closely as po

ViaNews Editorial Team (Europe)•Feb 18, 2026

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed

Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,366 source documents archived

Query this data → isubstrate.com